ClinicalTrials.gg
CompletedNCT00471497ENESTndUpdated Nov 18, 2020Results posted

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

A Phase 3 interventional study of nilotinib and imatinib in Myelogenous Leukemia, Chronic, sponsored by Novartis Pharmaceuticals. Completed at 213 sites in 35 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
846
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
Largest of 66
846 · median 55
Started
2007
with 2 others
Phase 3
15 of 66
none open now
Registered
6th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one has the largest enrollment, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 6th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia chromosome-positive (Ph+) Chronic Myelogenous Leukemia in the chronic phase (CML-CP).

An extension protocol was included in this study design to allow patients who did not show sufficient response to their assigned treatments the opportunity to receive imatinib 400 mg BID (option available until protocol amendment 7) or nilotinib 400 mg BID, using an abbreviated safety and efficacy assessment schedule.

Read the detailed description

Primary objectives of this study:

  • Compared the efficacy (major molecular response (MMR) rate at 12 months) of nilotinib at 400 mg bid with that of imatinib 400 mg qd in newly diagnosed, previously untreated Ph+ CML-CP patients.
  • Compared the efficacy (MMR rate at 12 months) of nilotinib at 300 mg bid with that of imatinib 400 mg qd in newly diagnosed, previously untreated Ph+ CML-CP patients.

The Primary objectives of Extension Phase of the study:

  • Characterized the safety and tolerability profile of nilotinib 400 mg BID after failure of imatinib or insufficiently responded to nilotinib 300 mg BID therapy and the safety and tolerability profile of imatinib therapy after failure of nilotinib therapy.

The study was designed to determine whether the treatment of newly diagnosed, previously untreated Ph+ CML-CP patients with either nilotinib 300 mg bid or 400 mg bid demonstrated improved efficacy compared to imatinib 400 mg qd. The primary efficacy endpoint was the rate of MMR defined as the proportion of patients who achieved ≥ 3 log reduction in BCR-ABL transcripts compared to either the standardized Baseline established in the IRIS trial (International Randomized Interferon versus STI571) (Cortes et al 2005) or to the BCR-ABL ratio ≤ 0.1% by International Scale, as detected by real-time quantitative polymerase chain reaction (RQ-PCR) at 12 months.

The key secondary endpoint was to compare the rate of durable MMR between nilotinib 300 mg bid with that of imatinib, and of nilotinib 400 mg bid with that of imatinib at 24 months. This report presents the final results of efficacy and safety at the LPLV (21-Aug-2019).

The main data analysis was done at the time when all patients completed 12 cycles of treatment (or discontinued earlier). There were two primary comparisons at this time point: the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg, and the MMR rate of the nilotinib 300 mg versus the MMR rate of the imatinib 400 mg. Comparisons were done sequentially, i.e. the MMR rate of nilotinib 400 mg versus the MMR rate of imatinib 400 mg was to be compared first; if it was significant at 5% level, the MMR rate of the nilotinib 300 mg versus the MMR rate of the imatinib 400 mg was to be compared. The study had a 90% power to detect a 15% difference between the nilotinib 400 mg arm versus imatinib 400 mg arm assuming that the MMR rate of imatinib is 40% and the MMR rate of nilotinib is 55%. The study also had a 90% power to detect a 15% difference between the nilotinib 300 mg and the imatinib 400 mg arms, if the comparison between the nilotinib 400 mg and the imatinib 400 mg was significant.

The second main data analysis was done at the time when all patients completed 24 cycles of treatment (or discontinued earlier). There were two key comparisons at this time point: the rate of durable MMR at 24 months of the nilotinib 400 mg versus the imatinib 400 mg, and the rate of durable MMR at 24 months of the nilotinib 300 mg versus the imatinib 400 mg.

In order to control the overall type I error rate at or below 5%, only when the corresponding comparison on the primary efficacy endpoint(s) was (were) significant, the key secondary comparison(s) of the respective nilotinib doses (400 mg bid and/or 300 mg bid) versus imatinib 400 mg qd were tested at two-sided 5% significance level.

Patients participating after demonstrating suboptimal response/treatment failure to their assigned study treatment in the core study were offered the option to continue in the extension study and to receive imatinib 400 mg bid (option available only until protocol amendment 7) or nilotinib therapy at a dose of 400 mg bid.

03

Conditions studied

  • Myelogenous Leukemia, Chronic

Keywords

  • leukemia
  • bone marrow
  • leukemia symptoms
  • lukemia
  • cml
  • complete blood count
  • lymphocyte
  • blood cancer
  • leukocytes
  • chronic leukemia
  • bone marrow biopsy
  • leukemia research
  • leukemia cells
  • bone marrow disease
  • chronic myeloid leukemia
  • blood cancer symptoms
  • white blood cell diseases
  • chronic myelogenous leukemia
  • leukemia treatment
  • leukemia facts
  • leucemia
  • facts about leukemia
  • myelogenous leukemia
  • newly diagnosed CML
  • newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.
  • Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome of (9:22) translocations

Key Exclusion criteria:

  • Previously documented T315I mutation
  • Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib
  • Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
  • Impaired cardiac function.
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
  • Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
  • Currently receiving treatment with any medications that have the potential to prolong the .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
846 participants (actual)

Study arms

  • Experimental
    nilotinib 300mg bid (investigating arm)

    Drug: nilotinib

  • Experimental
    Nilotinb 400 mg bid (investigating arm)

    Drug: nilotinib

  • Experimental
    imatinib 400mg QD (control arm)

    Drug: imatinib

Interventions

  • Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.

    Also known as: AMN107

  • Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).

    Also known as: STI571

06

What researchers measure

Primary outcomes

  1. Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation

    MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.

    Time frame: Baseline, 12 months

  2. Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation

    MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.

    Time frame: 12 months

Secondary outcomes

  1. Rates of Durable MMR at 24 Months Between All 3 Arms

    Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.

    Time frame: 24 months

  2. Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months

    CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as "Nocomplete cytogenetic response".

    Time frame: 12, 24, 36, 48, 60, 72 months (M)

  3. Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms

    MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.

    Time frame: 12 months

  4. Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms

    MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.

    Time frame: 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months

  5. Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib

    Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)

    Time frame: at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months

  6. Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib

    This is the molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)

    Time frame: at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months

  7. Time to First MMR

    Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.

    Time frame: up to 84 months

  8. Duration of MMR

    Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.

    Time frame: approx. 11 years

  9. Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts

    Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.

    Time frame: up to 84 months

  10. Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts

    It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.

    Time frame: approx. 11 years

  11. Rate of Hematologic Response

    Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).

    Time frame: 12 months, 24 months, Overall on Core study (approx. 11 years)

  12. Time to Complete Cytogenic Response (CCyR)

    Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR

    Time frame: 24 months

  13. Duration of CCyR

    Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.

    Time frame: up to 72 months

  14. Progression-free Survival (PFS)

    Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study

    Time frame: approx. 11 years

  15. Event-free Survival (EFS)

    Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR

    Time frame: approx. 11 years

  16. Overall Survival (OS)

    OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.

    Time frame: approx. 11 years

  17. Actual Dose-intensity

    Actual dose intensity is defined as total dose over time on treatment

    Time frame: approx. 11 years

  18. Time to Progression to AP/BC

    Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.

    Time frame: approx. 11 years

  19. Pharmacokinetics: Cmax

    Cmax is defined as the maximum serum concentration after dose

    Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration

  20. Pharmacokinetics: Cmin

    Cmin is defined as the minimum serum concentration after dose

    Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration

  21. Pharmacokinetics: Tmax

    Tmax is defined as the sampling time when maximum measured serum concentration occurs

    Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration

  22. Pharmacokinetics: AUC0-last

    AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method

    Time frame: any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration

  23. Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

    Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).

    Time frame: Overall for Extension study for approx. 10 years

  24. Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

    Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.

    Time frame: Overall for Extension study for approx. 10 years

  25. Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

    Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))

    Time frame: Overall for Extension study for approx. 10 years

  26. Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

    Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)

    Time frame: Overall for Extension study for approx. 10 years

  27. Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

    Molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)

    Time frame: Overall for Extension study for approx. 10 years

  28. Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)

    This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.

    Time frame: Overall for Extension study for approx. 10 years

07

Results

Posted Jun 17, 2013

Participant flow

The study over-enrolled, and 846 patients (283 in the imatinib 400 mg arm, 282 in the nilotinib 300 mg arm and 281 in the nilotinib 400 mg arm) were randomized. DP = disease progression, SOR/TF = Suboptimal response or treatment failure

Core Treatment Phase
Participant flow — Core Treatment Phase
MilestoneImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Started283282281
Safety analysis set280279277
Discon. core/did not enter ext.235256278
Discontinued core/entered ext.48263
Completed9910799
Not completed184175182
Withdrew: Abnormal laboratory values399
Withdrew: Abnormal test procedures101
Withdrew: Condition no longer requires study drug010
Withdrew: Withdrawal by subject312934
Withdrew: Lost to follow-up663
Withdrew: Death393
Withdrew: Disease progression1024
Withdrew: Protocol violation61511
Withdrew: Sub optimal response or treat. failure191113
Withdrew: Administrative problems141412
Withdrew: Adverse event435389
Withdrew: Disc. core/entered ext. - dp progression200
Withdrew: Disc. core/entered ext.- sor/tf46263
Extension Phase
Participant flow — Extension Phase
MilestoneImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Started48263
Completed21122
Not completed27141
Withdrew: Adverse event951
Withdrew: Unsatisfactory therapeutic effect860
Withdrew: Withdrawal by subject310
Withdrew: Lost to follow-up200
Withdrew: Death100
Withdrew: Disease progression200
Withdrew: Protocol violation220

Outcome measures

PrimaryMajor Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation

MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.

Time frame:
Baseline, 12 months
Reported as:
Number · Percentage of participants
Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation22.3 (17.6 to 27.6)44.3 (38.4 to 50.3)42.7 (36.8 to 48.7)
Statistical analysis
  • Imatinib 400 mg QD vs Nilotinb 300 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response rate: 22.1 · 95% CI 14.5 to 29.6
  • Imatinib 400 mg QD vs Nilotinib 400 mg BID · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in response rate: 20.4 · 95% CI 12.9 to 28.0
PrimaryPercentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation

MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With MMR at 12 Months Between All 3 Arms by Sokal Risk Group With Imputation
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Sokal risk group = Low26.0 (17.9 to 35.5)40.8 (31.2 to 50.9)53.4 (43.3 to 63.3)
Sokal risk group = Interm.22.8 (15.0 to 32.2)50.5 (40.4 to 60.6)40.0 (30.3 to 50.3)
Sokal risk group = High16.7 (9.2 to 26.8)41.0 (30.0 to 52.7)32.1 (21.9 to 43.6)
Statistical analysis
  • Imatinib 400 mg QD vs Nilotinb 300 mg BID · Difference in response rate: 14.8 · 95% CI 2.1 to 27.5
  • Imatinib 400 mg QD vs Nilotinib 400 mg BID · Difference in response rate: 27.4 · 95% CI 14.6 to 40.2
  • Imatinib 400 mg QD vs Nilotinb 300 mg BID · Difference in response rate: 27.7 · 95% CI 15.0 to 40.4
  • Imatinib 400 mg QD vs Nilotinib 400 mg BID · Difference in response rate: 17.2 · 95% CI 4.6 to 29.8
  • Imatinib 400 mg QD vs Nilotinb 300 mg BID · Difference in response rate: 24.4 · 95% CI 10.7 to 38.1
  • Imatinib 400 mg QD vs Nilotinib 400 mg BID · Difference in response rate: 15.4 · 95% CI 2.1 to 28.6
SecondaryRates of Durable MMR at 24 Months Between All 3 Arms

Durable MMR at 24 months is defined as having MMR both at 12 months and at 24 months, and with no documented loss of MMR between these 12 month and 24 month time points.

Time frame:
24 months
Reported as:
Number · Percentage of participants
Rates of Durable MMR at 24 Months Between All 3 Arms
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rates of Durable MMR at 24 Months Between All 3 Arms20.5 (15.9 to 25.7)41.8 (36.0 to 47.8)39.1 (33.4 to 45.1)
Statistical analysis
  • Imatinib 400 mg QD vs Nilotinb 300 mg BID · Difference in response rate: 21.3 · 95% CI 13.9 to 28.8
  • Imatinib 400 mg QD vs Nilotinib 400 mg BID · Difference in response rate: 18.7 · 95% CI 11.3 to 26.0
SecondaryRate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months

CCyR is defined as 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Patients with no CCyR as the best response by any specific time point, all missing cytogenetic evaluations by that time point or Ph- at baseline are combined as "Nocomplete cytogenetic response".

Time frame:
12, 24, 36, 48, 60, 72 months (M)
Reported as:
Number · Percentage of participants
Rate of Complete Cytogenetic Response (CCyR) in Nilotinib Treatment Arms With Imatinib at 12 Months and Beyond 12 Months
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
CCyR at M1255.570.268.7
CCyR at M2461.566.066.2
CCyR at M3614.19.212.8
CCyR at M4811.38.913.5
CCyR at M602.52.82.8
CCyR at M721.81.82.8
SecondaryRate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms

MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 12 months based on 12-month cut-off interim data.

Time frame:
12 months
Reported as:
Number · Percentage of participants
Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms
Percentage of participantsNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of Major Molecular Response (MMR) at 12 Months Between Two Nilotinib Arms44.3 (38.4 to 50.3)42.7 (36.8 to 48.7)
Statistical analysis
  • Nilotinb 300 mg BID vs Nilotinib 400 mg BID · Cochran-Mantel-Haenszel · p = 0.6987 · Absolute difference: -1.6 · 95% CI -9.8 to 6.6
SecondaryRate of MMR at 6 Months and Beyond in All 3 Treatment Arms

MMR is defined as the percentage of participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR)) at 6 months and beyond up to 120 months based on final data.

Time frame:
6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Reported as:
Number · Percentage of participants
Rate of MMR at 6 Months and Beyond in All 3 Treatment Arms
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
MMR at M612.0 (8.5 to 16.4)33.0 (27.5 to 38.8)29.5 (24.3 to 35.2)
MMR at M1222.3 (17.6 to 27.6)44.7 (38.8 to 50.7)43.1 (37.2 to 49.1)
MMR at M2437.5 (31.8 to 43.4)61.7 (55.8 to 67.4)59.1 (53.1 to 64.9)
MMR at M3638.5 (32.8 to 44.5)59.2 (53.2 to 65.0)57.3 (51.3 to 63.2)
MMR at M4843.8 (38.0 to 49.8)59.9 (54.0 to 65.7)55.2 (49.1 to 61.1)
MMR at M6049.1 (43.2 to 55.1)62.8 (56.8 to 68.4)61.2 (55.2 to 66.9)
MMR at M7241.7 (35.9 to 47.7)52.5 (46.5 to 58.4)57.7 (51.6 to 63.5)
MMR at M8440.3 (34.5 to 46.3)50.0 (44.0 to 56.0)50.9 (44.9 to 56.9)
MMR at M9637.5 (31.8 to 43.4)46.1 (40.2 to 52.1)46.3 (40.3 to 52.3)
MMR at M10837.5 (31.8 to 43.4)43.3 (37.4 to 49.3)40.2 (34.4 to 46.2)
MMR at M12036.4 (30.8 to 42.3)37.9 (32.3 to 43.9)39.1 (33.4 to 45.1)
SecondaryRate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib

Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)

Time frame:
at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Reported as:
Number · Percentage of participants
Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Molecular response of <=0.01% at 6 months1.1 (0.2 to 3.1)8.9 (5.8 to 12.8)5.7 (3.3 to 9.1)
Molecular response of <=0.01% at 12 months3.9 (2.0 to 6.8)12.1 (8.5 to 16.4)8.9 (5.8 to 12.9)
Molecular response of <=0.01% at 24 months10.2 (7.0 to 14.4)24.5 (19.6 to 29.9)22.1 (17.4 to 27.4)
Molecular response of <=0.01% at 36 months14.1 (10.3 to 18.7)29.4 (24.2 to 35.1)23.8 (19.0 to 29.3)
Molecular response of <=0.01% at 48 months19.8 (15.3 to 24.9)33.0 (27.5 to 38.8)29.9 (24.6 to 35.6)
Molecular response of <=0.01% at 60 months31.1 (25.7 to 36.8)47.9 (41.9 to 53.9)43.4 (37.5 to 49.4)
Molecular response of <=0.01% at 72 months27.2 (22.1 to 32.8)44.3 (38.4 to 50.3)45.2 (39.3 to 51.2)
Molecular response of <=0.01% at 84 months29.0 (23.8 to 34.6)42.9 (37.1 to 48.9)40.6 (34.8 to 46.6)
Molecular response of <=0.01% at 96 months28.3 (23.1 to 33.9)39.7 (34.0 to 45.7)38.1 (32.4 to 44.0)
Molecular response of <=0.01% at 108 months32.2 (26.7 to 37.9)40.4 (34.6 to 46.4)34.9 (29.3 to 40.8)
Molecular response of <=0.01% at 120 months28.3 (23.1 to 33.9)35.5 (29.9 to 41.4)33.8 (28.3 to 39.7)
SecondaryRate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib

This is the molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)

Time frame:
at 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120 months
Reported as:
Number · Percentage of participants
Rate of a ≥ 4.5 Log Reduction in BCR-ABL Transcripts in Nilotinib Treatment Arms With Imatinib
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Molecular response of <=0.0032% at 6 months0.0 (0.0 to 1.3)3.5 (1.7 to 6.4)1.4 (0.4 to 3.6)
Molecular response of <=0.0032% at 12 months0.4 (0.0 to 2.0)4.6 (2.5 to 7.8)5.0 (2.8 to 8.2)
Molecular response of <=0.0032% at 24 months2.8 (1.2 to 5.5)12.4 (8.8 to 16.8)7.8 (5.0 to 11.6)
Molecular response of <=0.0032% at 36 months8.1 (5.2 to 11.9)13.8 (10.0 to 18.4)12.1 (8.5 to 16.5)
Molecular response of <=0.01032 at 48 months10.2 (7.0 to 14.4)16.3 (12.2 to 21.2)17.1 (12.9 to 22.0)
Molecular response of <=0.0032% at 60 months19.8 (15.3 to 24.9)32.3 (26.8 to 38.1)29.5 (24.3 to 35.2)
Molecular response of <=0.0032% at 72 months18.0 (13.7 to 23.0)31.2 (25.8 to 37.0)28.8 (23.6 to 34.5)
Molecular response of <=0.0032% at 84 months19.1 (14.7 to 24.2)31.6 (26.2 to 37.3)28.8 (23.6 to 34.5)
Molecular response of <=0.01% at 96 months23.3 (18.5 to 28.7)31.9 (26.5 to 37.7)32.4 (26.9 to 38.2)
Molecular response of <=0.0032% at 108 months24.0 (19.2 to 29.4)31.9 (26.5 to 37.7)28.1 (22.9 to 33.8)
Molecular response of <=0.0032% at 120 months21.2 (16.6 to 26.4)27.0 (21.9 to 32.5)25.6 (20.6 to 31.1)
SecondaryTime to First MMR

Time to MMR is defined as time from date of randomization to the date of the first documented MMR in nilotinib treatment arms, compared to imatinib in adult patients with Ph+ CML in CP.

Time frame:
up to 84 months
Reported as:
Median · Months
Time to First MMR
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Time to First MMR14.13 (11.60 to 17.31)8.31 (6.21 to 8.48)8.53 (8.31 to 11.07)
SecondaryDuration of MMR

Duration of MMR for patients with MMR is defined as the time between date of MMR and the earliest of the following: loss of MMR, CML-related death or progression to AP/BC during study treatment The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.

Time frame:
approx. 11 years
Reported as:
Median · Months
Duration of MMR
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Duration of MMRNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryTime to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts

Time to BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% is defined as: date of first BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% - date of randomization +1.

Time frame:
up to 84 months
Reported as:
Median · Months
Time to Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
time to first molecular response of <=0.01%30.46 (24.11 to 36.01)19.38 (16.62 to 22.34)22.70 (19.48 to 27.63)
time to first molecular response of <=0.0032%37.29 (33.45 to 41.63)32.46 (23.23 to 38.67)35.94 (30.39 to 41.00)
SecondaryDuration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts

It is defined as the time from the date of first documented BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032% to the earliest of the following: Loss of BCR-ABL ratio of ≤ 0.01% and ≤ 0.0032%, respectively, CML-related death or progression to AP/BC during study treatment. The time will be censored at last molecular assessment (PCR) date for patients for whom none of the above events is reported.

Time frame:
approx. 11 years
Reported as:
Median · Months
Duration of Both a ≥ 4 and ≥ 4.5 Log Reduction in BCR-ABL Transcripts
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
duration of first molecular response of <=0.01%NA (NA to NA)NA (NA to NA)NA (NA to NA)
duration of first molecular response of <=0.0032%NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryRate of Hematologic Response

Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).

Time frame:
12 months, 24 months, Overall on Core study (approx. 11 years)
Reported as:
Number · Percentage of participants
Rate of Hematologic Response
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Complete hematologic response (CHR) by M1293.3 (89.7 to 95.9)90.1 (86.0 to 93.3)89.0 (84.7 to 92.4)
CHR by M2493.6 (90.1 to 96.2)90.8 (86.8 to 93.9)90.4 (86.3 to 93.6)
CHR Overall94.0 (90.6 to 96.5)92.2 (88.4 to 95.0)90.7 (86.7 to 93.9)
SecondaryTime to Complete Cytogenic Response (CCyR)

Time to CCyR is defined as the time from the date of randomization to the date of first documented CCyR

Time frame:
24 months
Reported as:
Median · Months
Time to Complete Cytogenic Response (CCyR)
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Time to Complete Cytogenic Response (CCyR)8.5 (5.8 to 10.9)5.7 (5.6 to 5.7)5.7 (5.7 to 5.8)
SecondaryDuration of CCyR

Duration of CCyR is defined as the time from date of first documented CCyR to the earliest date of loss of CCyR.

Time frame:
up to 72 months
Reported as:
Median · Months
Duration of CCyR
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Duration of CCyRNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryProgression-free Survival (PFS)

Progression-free survival is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring in the core or extension study, or during the follow-up period after discontinuation of core or extension study

Time frame:
approx. 11 years
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Progression-free Survival (PFS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryEvent-free Survival (EFS)

Event-free survival is defined as the time from the date of randomization to the date of first occurrence of any of the following: death due to any cause (if death is the primary reason for discontinuation), progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR

Time frame:
approx. 11 years
Reported as:
Median · Months
Event-free Survival (EFS)
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Event-free Survival (EFS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from the date of randomization to the date death. Up to 10 calendar years of follow up from the date when the last patient randomized received the first dose of study drug in all active treatment arms of adult patients with Ph+ CML CP.

Time frame:
approx. 11 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryActual Dose-intensity

Actual dose intensity is defined as total dose over time on treatment

Time frame:
approx. 11 years
Reported as:
Median · mg/day
Actual Dose-intensity
mg/dayImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Actual Dose-intensity400.0 (206 to 800)591.1 (186 to 699)758.9 (232 to 800)
SecondaryTime to Progression to AP/BC

Time to progression to AP/BC is defined as the time from the date of randomization to the date of event defined as the first documented disease progression to AP/BC or the date of CML related death.

Time frame:
approx. 11 years
Reported as:
Median · Months
Time to Progression to AP/BC
MonthsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Time to Progression to AP/BCNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryPharmacokinetics: Cmax

Cmax is defined as the maximum serum concentration after dose

Time frame:
any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Reported as:
Median · ng/mL
Pharmacokinetics: Cmax
ng/mLNilotinb 300 mg BIDNilotinib 400 mg BID
Pharmacokinetics: Cmax1555 (1340 to 2300)1440 (1002 to 2125)
SecondaryPharmacokinetics: Cmin

Cmin is defined as the minimum serum concentration after dose

Time frame:
any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Reported as:
Median · ng/mL
Pharmacokinetics: Cmin
ng/mLNilotinb 300 mg BIDNilotinib 400 mg BID
Pharmacokinetics: Cmin1430 (1250 to 1740)915 (752 to 2080)
SecondaryPharmacokinetics: Tmax

Tmax is defined as the sampling time when maximum measured serum concentration occurs

Time frame:
any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Reported as:
Median · hour (h)
Pharmacokinetics: Tmax
hour (h)Nilotinb 300 mg BIDNilotinib 400 mg BID
Pharmacokinetics: Tmax1.47 (0.50 to 2.04)1.50 (0.00 to 2.02)
SecondaryPharmacokinetics: AUC0-last

AUC0-last is defined as area under concentration-time curve from time zero to the last measurable sample, calculated by log-linear trapezoidal method

Time frame:
any day after day 8 up to cycle 12 (each cycle = 28 days) and after at least 3 consecutive days without dose interruption or dose modification at pre-dose (0 hour), 1 hour, 2 hours, 3 hours, 5 hours, 8 hours, and 12 hours after dose administration
Reported as:
Median · h.ng/mL
Pharmacokinetics: AUC0-last
h.ng/mLNilotinb 300 mg BIDNilotinib 400 mg BID
Pharmacokinetics: AUC0-last14446 (12806 to 17411)11689 (7925 to 18678)
SecondaryRate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

Rate of hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes \< 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of Hematologic Response on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)83.3 (69.8 to 92.5)84.6 (65.1 to 95.6)66.7 (9.4 to 99.2)
SecondaryRate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

Rate of CCyR is defined as the percentage of participants in complete cytogenetic response (CCyR). CcyR is defined as 0% of Ph+ metaphases in the bone marrow.

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of Complete Cytogenetic Response (CCyR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)72.9 (58.2 to 84.7)73.1 (52.2 to 88.4)66.7 (9.4 to 99.2)
SecondaryRate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

Rate of MMR is defined as the percentage pf participants in MMR (reduction of ≥ 3 logs in BCR-ABL transcripts compared to the standardized baseline established in IRIS, or ≤ 0.1% BCR-ABL/ABL % by international scale and measured by real-time quantitative polymerase chain reaction (RQ-PCR))

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of Major Molecular Response (MMR) on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)64.6 (49.5 to 77.8)73.1 (52.2 to 88.4)66.7 (9.4 to 99.2)
SecondaryRate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

Molecular response of \<=0.01% is defined as BCR-ABL ratio (%) on IS \<= 0.01% (corresponds to \>=4 log reduction of BCR-ABL transcripts from standardized baseline value)

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of a ≥ 4 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)43.8 (29.5 to 58.8)57.7 (36.9 to 76.6)33.3 (0.8 to 90.6)
SecondaryRate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)

Molecular response of \<=0.0032% is defined as BCR-ABL ratio (%) on IS \<= 0.0032% (corresponds to \>=4.5 log reduction of BCR-ABL transcripts from standardized baseline value)

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Rate of ≥ 4.5 Log Reduction in BCR-ABL Transcripts on Nilotinib 400 mg BID Therapy After Insufficient Response During Core Treatment and Switch to Extension Phase (Extension)35.4 (22.2 to 50.5)38.5 (20.2 to 59.4)33.3 (0.8 to 90.6)
SecondaryPresence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)

This is the percentage of patients with any emergent mutation on extension treatment. The mutation comprised of T315T, less sensitive to nilotinib, unknown and sensitive to nilotinib.

Time frame:
Overall for Extension study for approx. 10 years
Reported as:
Number · Percentage of participants
Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)
Percentage of participantsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
Presence of Newly Observed BCR-ABL Mutations in Patients Post-baseline and Correlate With Response to Treatment With Imatinib and Nilotinib (Extension)20.811.533.3
Post-hocAll Collected Deaths

On treatment deaths were collected from first patient first visit up to 28 days after study treatment discontinuation (approx. 11 years). Patients with cancer were also followed up for overall survival until the end of the trial (to collect any deaths occurring more than 28 days after study drug discontinuation). In this study, one death was collected after randomization but before the participant received study drug.

Time frame:
From FPFV up to 28 days post treatment (approx. 11 years), From FPFV to LPLV (approx. 12 years)
Reported as:
Number · deaths
All Collected Deaths
deathsImatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BID
On-treatment deaths4105
Total deaths293223

Adverse events

Collected over Adverse Event (AE) time frame: Adverse events were collected from first dose of study treatment until end of study treatment plus 28 days post treatment, up to maximum duration of approx. 11 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib 400 mg QD4/280 (1.4%)96/280 (34.3%)275/280 (98.2%)
Nilotinib 300 mg BID10/279 (3.6%)112/279 (40.1%)276/279 (98.9%)
Nilotinib 400 mg BID5/277 (1.8%)126/277 (45.5%)272/277 (98.2%)
All Patients19/836 (2.3%)334/836 (40%)823/836 (98.4%)
Most frequent serious events
Showing 10 of 446
Most frequent serious events
EventImatinib 400 mg QDNilotinib 300 mg BIDNilotinib 400 mg BIDAll Patients
Angina pectorisCardiac disorders1/2803/27911/27715/836
Coronary artery diseaseCardiac disorders1/2804/27910/27715/836
PneumoniaInfections and infestations9/2806/2796/27721/836
Myocardial infarctionCardiac disorders2/2804/2796/27712/836
Abdominal painGastrointestinal disorders2/2805/2796/27713/836
Back painMusculoskeletal and connective tissue disorders2/2802/2796/27710/836
PyrexiaGeneral disorders2/2806/2795/27713/836
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders5/2806/2790/27711/836
AnaemiaBlood and lymphatic system disorders4/2802/2795/27711/836
Acute myocardial infarctionCardiac disorders0/2802/2795/2777/836
Most frequent other events
Showing 10 of 91
Most frequent other events
EventImatinib 400 mg QDNilotinib 300 mg BIDNilotinib 400 mg BIDAll Patients
DiarrhoeaGastrointestinal disorders137/28060/27967/277264/836
RashSkin and subcutaneous tissue disorders70/280112/279125/277307/836
NauseaGastrointestinal disorders120/28064/27989/277273/836
HeadacheNervous system disorders76/28097/279105/277278/836
Muscle spasmsMusculoskeletal and connective tissue disorders99/28040/27939/277178/836
Alanine aminotransferase increasedInvestigations39/28083/27987/277209/836
NasopharyngitisInfections and infestations69/28082/27967/277218/836
VomitingGastrointestinal disorders80/28046/27961/277187/836
ArthralgiaMusculoskeletal and connective tissue disorders67/28074/27965/277206/836
AnaemiaBlood and lymphatic system disorders71/28038/27945/277154/836

Baseline characteristics

Full analysis Set (FAS): Contained 846 randomized patients. Patients were analyzed according to the treatment they were randomized to, regardless of actual treatment received.

Age, Customized
Age, Customized(Participants)Imatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BIDTotal
<35 years636765195
>= 35 - <45 years675059176
>=45 - <55 years637265200
>=55 - < 65 years555765177
>=65 years35362798
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BIDTotal
Female125124106355
Male158158175491
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Imatinib 400 mg QDNilotinb 300 mg BIDNilotinib 400 mg BIDTotal
Caucasian187170185542
Black7121130
Asian717666213
Native American1023
Other17241758
08

Study locations

213 sites
  • University of California at Los Angeles Dept. of Hematology Clinic
    Los Angeles, California 90095, United States
  • Kaiser Permanente - California Southern Dept of Kaiser South 3
    San Diego, California 92120, United States
  • Kaiser Permanente - California Northern Vallejo Med Center/Med Offices
    Vallejo, California 94589, United States
  • Kaiser Permanente - California Northern Kaiser Med
    Vallejo, California 94609, United States
  • Rocky Mountain Cancer Centers RMCC - Colorado Springs
    Greenwood Village, Colorado, United States
  • Florida Cancer Specialists Dept. FloridaCancerSpecialists
    Fort Myers, Florida 33901, United States
  • Advanced Medical Specialties Research Dept.
    Miami, Florida 33176, United States
  • Cancer Centers of Florida PA Cancer Centers of FL
    Ocoee, Florida 34761, United States
  • Florida Retina Institute Flordia Cancer Affilates
    Orlando, Florida 32804, United States
  • University of Chicago Section of Hematology/Oncology
    Chicago, Illinois 60637, United States
  • Indiana Blood and Marrow Institute Dept. of Indiana Blood&Marrow
    Beech Grove, Indiana 46107, United States
  • University of Iowa Hospitals and Clinics Dept.of U of Iowa Hosp&Clinics
    Iowa City, Iowa 52242, United States
  • Kansas City Cancer Center KCCC Business Office
    Overland Park, Kansas 66210, United States
  • LSU HEALTH SCIENCES CENTER/ LSU SCHOOL OF MEDICINE Feist-Weiller Cancer Center
    New Orleans, Louisiana 70115, United States
  • Michigan State University / Breslin Cancer Center Breslin Cancer Center
    Lansing, Michigan 48824, United States
  • Missouri Cancer Associates Dept. of Boone Hospital Center
    Columbia, Missouri 65201, United States
  • Hematology Oncology Consultants, Inc. Deptof Hem. Onc.Consunsultants
    Saint Louis, Missouri 63136, United States
  • Hackensack University Medical Center Department of Research
    Hackensack, New Jersey 07601, United States
  • Memorial Sloan Kettering Cancer Center Clinical Trials Office
    New York, New York 10021, United States
  • University of North Carolina UNC Lineberger Cancer Center
    Chapel Hill, North Carolina 27514, United States
  • Wake Forest University Health Sciences Dept. of Industry Research
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati / Barrett Cancer Center Dept.of Internal Med.
    Cincinnati, Ohio 45219, United States
  • Cleveland Clinic Foundation CCF
    Cleveland, Ohio 44195, United States
  • Northwest Cancer Specialists Compass Oncology -BKM
    Portland, Oregon 97210, United States
  • Cancer Centers of the Carolinas CC of C -Eastside
    Greenville, South Carolina 29605, United States
  • Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology
    Chattanooga, Tennessee 37404, United States
  • Tennessee Oncology Dept. of Centennial Medical
    Nashville, Tennessee 37203, United States
  • Texas Cancer Center ( Medical City Dallas Hospital)
    Dallas, Texas 75230, United States
  • Cancer Care Centers of South Texas HOAST CCC of So.TX- Medical Center
    San Antonio, Texas 78229, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1221ADC, Argentina
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902AVG, Argentina
  • Novartis Investigative Site
    Salzburg, 5020, Austria
  • Novartis Investigative Site
    Wien, A-1090, Austria
  • Novartis Investigative Site
    Bruxelles, 1000, Belgium
  • Novartis Investigative Site
    Charleroi, 6000, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Yvoir, 5530, Belgium
  • Novartis Investigative Site
    Brasilia, DF 70330-150, Brazil
  • Novartis Investigative Site
    Curitiba, PR 80060-900, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20211-030, Brazil
  • Novartis Investigative Site
    Campinas, SP 13083-970, Brazil
  • Novartis Investigative Site
    Jau, SP 17210-080, Brazil
  • Novartis Investigative Site
    Sao Paulo, SP 05403 000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01224-000, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01401-901, Brazil
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E3, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Quebec, G1J 1Z4, Canada
  • Novartis Investigative Site
    Quebec, G1R 2J6, Canada
  • Novartis Investigative Site
    Bogota, Cundinamarca 110111, Colombia
  • Novartis Investigative Site
    Bogota, 110001, Colombia
  • Novartis Investigative Site
    Praha 2, Czech Republic 128 20, Czechia
  • Novartis Investigative Site
    Olomouc, CZE 775 20, Czechia
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Vejle, DK-7100, Denmark
  • Novartis Investigative Site
    Cairo, Egypt
  • Novartis Investigative Site
    HUS Helsinki, FIN-00029, Finland
  • Novartis Investigative Site
    Turku, FIN-20521, Finland
  • Novartis Investigative Site
    Paris Cedex 10, Cedex 10 75475, France
  • Novartis Investigative Site
    Caen, Cedex 14033, France
  • Novartis Investigative Site
    Saint Priest en Jarez, Loire 42270, France
  • Novartis Investigative Site
    Angers Cedex 1, 49033, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Creteil, 94010, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Marseille, 13273, France
  • Novartis Investigative Site
    Nantes, 44035, France
  • Novartis Investigative Site
    Nice Cedex, 06202, France
  • Novartis Investigative Site
    Pierre Benite Cedex, 69495, France
  • Novartis Investigative Site
    Poitiers, 86000, France
  • Novartis Investigative Site
    Rennes, 35019, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Vandoeuvre les Nancy, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Eisenach, 99817, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50937, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Muenchen, 81675, Germany
  • Novartis Investigative Site
    Ulm, 89081, Germany
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Budapest, 1097, Hungary
  • Novartis Investigative Site
    Alessandria, AL 15100, Italy
  • Novartis Investigative Site
    Ancona, AN 60126, Italy
  • Novartis Investigative Site
    Bergamo, BG 24127, Italy
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Catania, CT 95123, Italy
  • Novartis Investigative Site
    Firenze, FI 50134, Italy
  • Novartis Investigative Site
    Genova, GE 16132, Italy
  • Novartis Investigative Site
    Milano, MI 20162, Italy
  • Novartis Investigative Site
    Pescara, PE 65124, Italy

Showing the first 100 of 213 sites across 35 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. Epub 2014 Feb 14. PubMed 24532039 ↗
  • Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11. PubMed 24335106 ↗
  • Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15. PubMed 23502220 ↗
  • Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Muller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29. PubMed 23109697 ↗
  • Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. Eur J Clin Pharmacol. 2012 May;68(5):723-33. doi: 10.1007/s00228-011-1200-7. Epub 2011 Dec 30. PubMed 22207416 ↗
  • Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum In: Lancet Oncol. 2011 Oct;12(11):989. PubMed 21856226 ↗
  • Cortes JE, Hochhaus A, le Coutre PD, Rosti G, Pinilla-Ibarz J, Jabbour E, Gillis K, Woodman RC, Blakesley RE, Giles FJ, Kantarjian HM, Baccarani M. Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood. 2011 May 26;117(21):5600-6. doi: 10.1182/blood-2010-11-318949. Epub 2011 Apr 5. PubMed 21467546 ↗
  • Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. PubMed 20525993 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2007 to primary completion in Sep 2009, 25 months.

Results were first posted in Jun 2013, 3 years 9 months after primary completion.

Of 24 phase 3 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 79. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2007
First posted
May 10, 2007
StartActual
Jul 31, 2007
Primary completionActual
Sep 2, 2009
CompletionActual
Aug 21, 2019
Results first posted
Jun 17, 2013
Last update
Nov 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00471497
Responsible party
Sponsor
First posted
May 10, 2007
Start date
Jul 31, 2007
Primary completion
Sep 2, 2009
Completion
Aug 21, 2019
Results posted
Jun 17, 2013
Last update
Nov 18, 2020

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nilotinib · Imatinib

Start the discussion